Onconova Therapeutics Inc. (NASDAQ: ONTX) stock plunged by 8.37% at last close whereas the ONTX stock price gains by 6.42% in the pre-market trading session. Onconova Therapeutics is a clinical-stage biopharmaceutical corporation dedicated to the discovery and development of new cancer treatments. ONTX has developed patented selective anti-cancer agents that inhibit key cellular pathways involved in cancer cell proliferation.
What is about to come?
On May 10, 2021, ONTX announced that its first-quarter 2021 financial results would be released on Monday, May 17, 2021.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Read More
Recent Past Development
On April 22, 2021, ONTX confirmed that the first patient in an investigator-initiated Phase 2 trial to determine the effectiveness and protection of rigosertib in patients with RDEB-associated locally advanced/metastatic squamous cell carcinoma had been dosed (SCC). The patient was dosed at the University Hospital Salzburg, Austria’s EB House Austria, a center of excellence for epidermolysis bullosa. Additional research sites are expected to open in the UK and the US to investigate this unusual and debilitating disorder that is powered by genomics.
Given the different clinical presentations of the condition, which could determine the need for either oral or intravenous administration of rigosertib, 12 patients may receive either oral or intravenous rigosertib in this open-label investigator-initiated research. These individuals may have desquamation on their skin, making intravenous access impossible, or they may develop esophageal strictures, making oral administration difficult
Furthermore,
There are two key endpoints of this analysis. The first is to assess rigosertib’s anti-tumor behavior in RDEB patients with advanced SCC who have missed previous quality of care using the overall response rate (ORR), which is characterized as the percentage of patients who produce either a full or partial response (PR). The efficacy and tolerability of rigosertib in this population is the second primary endpoint. Quality of life and a biomarker examination of archival tissue from both patients are secondary research endpoints. Patients will be dosed for up to a year, with the experiment expected to last between two and a half years.
